StreetInsider.com News Articles

Form 10-Q Sunshine Biopharma Inc. For: Jun 30

Thu, 13 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26920904.html

Form 10-Q Sunshine Biopharma Inc. For: Jun 30

Thu, 13 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26920904.html

Form SCHEDULE 13G/A Sunshine Biopharma Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Thu, 13 Aug 2026 10:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26918141.html

Form SCHEDULE 13G/A Sunshine Biopharma Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Thu, 13 Aug 2026 10:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26918141.html

Form 4 Sunshine Biopharma Inc. For: Aug 07 Filed by: NATAN DAVID

Tue, 11 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260811/26906163.html

Form 4 Sunshine Biopharma Inc. For: Aug 07 Filed by: NATAN DAVID

Tue, 11 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260811/26906163.html

Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

Fri, 07 Aug 2026 09:00:00 -0400

Sunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengths
Launch expands Sunshine Biopharma's growing portfolio of essential prescription medications
Global Amoxicillin market projected to reach approximately $6.4 billion by 2031

FORT LAUDERDALE, FL / ACCESS Newswire / August 7, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the launch of its generic Amoxicillin formulation in the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to patients across Canada.

Amoxicillin,

Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

Fri, 07 Aug 2026 09:00:00 -0400

Sunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengths
Launch expands Sunshine Biopharma's growing portfolio of essential prescription medications
Global Amoxicillin market projected to reach approximately $6.4 billion by 2031

Amoxicillin,

Sunshine Biopharma gets Canadian approval for generic Dienogest tablets

Tue, 04 Aug 2026 09:02:39 -0400

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced it has received Canadian regulatory approval for its generic Dienogest 2mg tablets, the generic equivalent of the branded drug Visanne, used as a first-line therapy for pelvic pain associated with endometriosis.

The company said it expects the product to be ready to ship to Canadian pharmacies by the end of 2026. Distribution will be handled through its wholly owned Canadian subsidiary, Nora Pharma Inc.

According to market research firm Dataintelo, the global Dienogest market was valued at $2.8 billion in 2025 and is projected to reach $5.2 billion by 2034, at a compound annual growth rate

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval

Tue, 04 Aug 2026 09:00:00 -0400

Dienogest is first-line therapy for pelvic pain associate with endometriosis
The endometriosis treatment market is projected to reach $5.2 billion by 2034

FORT LAUDERDALE, FL / ACCESS Newswire / August 4, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Dienogest tablets of 2mg for the Canadian market. Dienogest is the generic equivalent of the brand name, Visanne^®.

Dienogest works through progesterone receptor binding, local anti-inflammatory actions, and mild hormone suppression. It reduces endometriosis

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval

Tue, 04 Aug 2026 09:00:00 -0400

Dienogest is first-line therapy for pelvic pain associate with endometriosis
The endometriosis treatment market is projected to reach $5.2 billion by 2034

Dienogest works through progesterone receptor binding, local anti-inflammatory actions, and mild hormone suppression. It reduces endometriosis

Form 8-K Sunshine Biopharma Inc. For: Aug 03

Mon, 03 Aug 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260803/26854709.html

Form 8-K Sunshine Biopharma Inc. For: Aug 03

Mon, 03 Aug 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260803/26854709.html

Health Canada approves Sunshine Biopharma's generic Ondansetron

Tue, 28 Jul 2026 08:04:03 -0400

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced that Health Canada has approved its generic Ondansetron tablets in 4mg and 8mg doses for the Canadian market, according to a company press release.

Ondansetron is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting associated with cancer chemotherapy, radiation therapy, and surgery. It is the generic equivalent of the brand-name drug Zofran. The company's approved formulations include standard film-coated tablets and Oral Disintegrating Tablets (ODT).

The company said it anticipates Ondansetron will be ready to ship to Canadian pharmacies by the end of 2026. Distribution will be handled through its wholly owned Canadian

Health Canada approves Sunshine Biopharma's generic Ondansetron

Tue, 28 Jul 2026 08:04:03 -0400

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced that Health Canada has approved its generic Ondansetron tablets in 4mg and 8mg doses for the Canadian market, according to a company press release.

The company said it anticipates Ondansetron will be ready to ship to Canadian pharmacies by the end of 2026. Distribution will be handled through its wholly owned Canadian

Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting

Tue, 28 Jul 2026 08:00:00 -0400

FORT LAUDERDALE, FL / ACCESS Newswire / July 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Ondansetron tablets of 4mg and 8mg for the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran^®.

Ondansetron is highly prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is a prescription serotonin 5-HT3 receptor antagonist. It works by blocking the actions of chemicals in the body that

Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting

Tue, 28 Jul 2026 08:00:00 -0400

Form 424B5 Sunshine Biopharma Inc.

Mon, 20 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260720/26790106.html

Form 424B5 Sunshine Biopharma Inc.

Mon, 20 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260720/26790106.html

Sunshine Biopharma sets up $4M at-the-market stock offering

Mon, 20 Jul 2026 16:28:56 -0400

Sunshine Biopharma, Inc. (NASDAQ: SBFM) entered into an at-the-market issuance sales agreement with Aegis Capital Corp. on July 20, 2026, allowing the company to sell up to $4,000,000 in common stock through the arrangement.

Under the agreement, Aegis Capital will act as exclusive sales agent, receiving a commission of 3.0% of gross proceeds from any shares sold. Sales may be conducted through the Nasdaq Capital Market or any other existing trading market for the company's common stock, using any method permitted under Rule 415(a)(4) of the Securities Act of 1933.

The company is not obligated to sell any shares, and the agent

Sunshine Biopharma sets up $4M at-the-market stock offering

Mon, 20 Jul 2026 16:28:56 -0400

The company is not obligated to sell any shares, and the agent

Form 8-K Sunshine Biopharma Inc. For: Jul 20

Mon, 20 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260720/26790006.html

Form 8-K Sunshine Biopharma Inc. For: Jul 20

Mon, 20 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260720/26790006.html

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

Mon, 20 Jul 2026 08:30:00 -0400

FORT LAUDERDALE, FL / ACCESS Newswire / July 20, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor, MR1-114, with nanomolar potency in at least three variants of the SARS-CoV-2 virus in vitro. MR1-114 was found to be efficacious in a mouse model of SARS-CoV-2 infection by repeated oral administration. This peer-reviewed study marks an important milestone for Sunshine Biopharma

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

Mon, 20 Jul 2026 08:30:00 -0400